Topic: Niagen
ChromaDex Receives Authorization for Niagen in EU, Australia
Los Angeles, CA—ChromaDex Corp. announced in a press release that it has received regulatory authorizations to sell its patented nicotinamide riboside chloride (branded Niagen)...
ChromaDex Initiates Study on NR, Aging
Los Angeles, CA—ChromaDex Corp announced in a press release the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the University of Florida,...
ChromaDex’s Niagen Demonstrates Safety, Efficacy in New Study
Los Angeles, CA—ChromaDex Corp. announced in a press release that a new study has further validated the safety and efficacy of ChromaDex’s proprietary form...
Form of B3 Linked to Breastfeeding Benefits in Mice
Iowa City, IA--A new animal study from researchers at the University of Iowa found that giving nursing rodents a supplemental form of vitamin B3...
ChromaDex Announces Q1 2017 Performance
Irvine, CA — ChromaDex announced its financial results for the first quarter (Q1) of 2017 ending on April 1, 2017. Net sales for Q1...
MULTIMEDIA
